Wire · opportunities
Moderna's mFlusiva becomes first mRNA influenza vaccine in US
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 August 2026 · Fusion42 review
The US FDA approved Moderna's Mflusiva, the first mRNA influenza vaccine, for adults 50 and older with full approval for ages 50-64 and accelerated approval with conditions for ages 65+. This approval marks a significant step for mRNA vaccine technology in influenza prevention and sets the stage for further regulatory reviews globally.
This Wire brief sits within Fusion42's coverage of Health, and 12 sources have reported it between 6 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
mRNA influenza vaccines are now a market reality in the US. If you work in infectious disease or vaccine development, urgent collaboration or pivot opportunities have emerged around mRNA platforms against seasonal flu.
◆ Coverage
12 sources · first reported 6 Aug 2026 · latest 27 Aug 2026
◆ Related on Wire
◆ Topics